The incidence of deep vein thrombosis (DVT) in the treatment of acute Achilles tendon rupture is reported to be between 0.3% and 50%.^[@bibr14-2325967120915909],[@bibr20-2325967120915909],[@bibr26-2325967120915909],[@bibr29-2325967120915909]^ Acute Achilles tendon rupture has an incidence of 20 to 32 per 100,000 individuals per year.^[@bibr17-2325967120915909],[@bibr19-2325967120915909]^ Patients with DVT have an up to 50% risk of developing postthrombotic syndrome, a condition associated with poor quality of life and significant societal costs.^[@bibr9-2325967120915909]^ Immobilization of the ankle joint has been suggested as a key element in the pathogenesis leading to DVT,^[@bibr11-2325967120915909],[@bibr14-2325967120915909]^ and intermittent pneumatic compression has been highly effective in reducing the incidence of DVT in patients with acute Achilles tendon rupture.^[@bibr14-2325967120915909]^

Treatment of Achilles tendon rupture differs among hospitals, regions, and countries; some use immobilization of the ankle joint for 6 to 10 weeks, while others use early controlled motion (ECM) of the ankle joint.^[@bibr7-2325967120915909]^ It has not been possible to show a clear superiority of one treatment protocol over another.^[@bibr4-2325967120915909],[@bibr15-2325967120915909],[@bibr21-2325967120915909],[@bibr32-2325967120915909],[@bibr33-2325967120915909],[@bibr37-2325967120915909]^ However, the question remains whether ECM of the ankle reduces the incidence of DVT and whether DVT negatively affects outcome after acute Achilles tendon rupture.

The primary objective of this study was to investigate whether ECM of the ankle joint in weeks 3 through 8 would reduce the incidence of DVT in patients with acute Achilles tendon rupture, compared with a treatment protocol where the ankle joint was immobilized for 8 weeks. Patients were treated nonoperatively, and full weightbearing was allowed from day 14 in both groups. A second objective was to determine the impact of DVT on outcomes after nonoperative treatment of acute Achilles tendon ruptures.

The main hypothesis was that ECM of the ankle joint would lead to a reduced risk of DVT. A secondary hypothesis was that DVT would lead to impaired outcome. The null hypotheses were that ECM would have no influence on the incidence of DVT and that DVT would not influence outcome.

Methods {#section1-2325967120915909}
=======

The study was performed as a secondary analysis of a randomized controlled trial (RCT) with patients allocated in a 1:1 ratio to 1 of 2 parallel groups. The main study investigated functional outcomes after acute Achilles tendon rupture.^[@bibr5-2325967120915909],[@bibr6-2325967120915909]^ The present study investigated the risk of developing DVT after acute Achilles tendon rupture. The detailed study design and protocol have been published previously.^[@bibr5-2325967120915909]^ The trial protocol was developed in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials)^[@bibr13-2325967120915909]^ and CONSORT (Consolidated Standards of Reporting Trials)^[@bibr22-2325967120915909]^ guidelines and checklists.

Study Participants {#section2-2325967120915909}
------------------

Eligible for inclusion were patients treated for acute Achilles tendon rupture at Copenhagen University Hospital Hvidovre who were age 18 to 70 years, were able to attend rehabilitation and postoperative examinations, and were able to speak and understand Danish. Patients were excluded if they had previous rupture of 1 or both Achilles tendons, had previous surgery on the affected Achilles tendon, were treated with fluoroquinolones or corticosteroids within the past 6 months, had arterial insufficiency in the legs (no palpable pulse in the dorsal pedis artery) or severe medical illness (American Society of Anesthesiologists score ≥3), or had a distance between the rupture and the calcaneus of less than 1 cm.

Patients were screened in the outpatient clinic within 14 days after rupture and, if eligible, were given the opportunity to decide whether they wanted to participate in the trial. Patients who did not participate were treated nonoperatively without ECM of the ankle joint.

Treatment and Intervention {#section3-2325967120915909}
--------------------------

In the emergency department, patients were treated with a posterior plaster splint in approximately 30° of plantarflexion (evaluated visually) and were referred for an appointment in the outpatient clinic within 4 days. In the outpatient clinic, the diagnosis was confirmed by an investigator, and a below-knee full synthetic cast was applied in approximately 30° (evaluated visually) of plantarflexion. No weightbearing was allowed for the first 2 weeks after injury.

After 2 weeks, the cast was removed. Each patient was placed in an Aircast AirSelect Standard orthosis (DJO LLC) with 2 wedges that each provided 1.5 cm of heel lift. Full weightbearing was allowed, but patients were advised to use the crutches for another 1 or 2 weeks. At this point, patients were randomized into 1 of 2 groups:Early controlled motion (ECM): The patient was instructed to perform early controlled ankle motion exercises from the beginning of week 3 through week 8.Immobilization (IM): The patient was instructed to wear the orthosis at all times and was not allowed to move the ankle before week 9. To ensure adherence to the protocol, a seal was applied around the orthosis via an 8-mm broad cable strip.

At both 4 and 6 weeks after rupture, patients were seen by the project nurse, and 1 wedge was removed at each visit. In the intervention (ECM) group, the training diary was inspected and patients were encouraged to perform their home exercises. In the control (IM) group, the seal of the boot was broken and the foot gently washed before the seal was reapplied. Both groups were instructed not to remove the orthosis at night. After 8 weeks, the orthosis was removed, and walking was allowed in standard running shoes. Crutches were used as needed, and the orthosis was used in situations of high strain or risk during weeks 9 through 12.

Rehabilitation from weeks 9 to 16 was organized as group exercises twice a week at the hospital and was identical for the 2 groups. A standardized rehabilitation program inspired by Willits et al^[@bibr36-2325967120915909]^ and Nilsson-Helander et al^[@bibr24-2325967120915909]^ was used. Please refer to the protocol paper for a full description of the program.^[@bibr5-2325967120915909]^

DVT Prophylaxis {#section4-2325967120915909}
---------------

DVT prophylaxis, in the form of rivaroxaban 10 mg once a day for the first 3 weeks, was to be given to participants at high risk of DVT. The high-risk population was defined as people with previous thromboembolic events, first-degree relatives with previous thromboembolic events, active cancer, body mass index greater than 40 kg/m^2^, or coagulopathy. Because none of the trial participants fulfilled these criteria, no DVT prophylaxis was given.

Intervention {#section5-2325967120915909}
------------

Participants performed ECM of the ankle joint while sitting on the edge of a table with both legs hanging. After allowing the foot to be pulled downward by gravity, the patient actively flexed the foot upward to a horizontal position ([Figure 1](#fig1-2325967120915909){ref-type="fig"}). This was performed at least 5 times a day in series of 25 repetitions. The treatment protocols for the 2 groups were similar except for the intervention.

![The intervention: early controlled motion of the ankle joint.](10.1177_2325967120915909-fig1){#fig1-2325967120915909}

Compliance {#section6-2325967120915909}
----------

The patients in the intervention group were equipped with training diaries and were encouraged to record their training for each of the 5 daily training sessions. For the patients in the control group, the orthosis was sealed with an 8-mm broad cable strip that could not be removed without use of industrial tools.

Outcomes {#section7-2325967120915909}
--------

The outcome measure was DVT at 2 or 8 weeks assessed with color Doppler sonography.^[@bibr1-2325967120915909]^ Investigations were performed by use of a GE LOGIQ E9 ultrasound machine with a linear 9-L ultrasound transducer. The color Doppler sonography examination followed a standard procedure covering the external iliac, common, deep and superficial femoral, popliteal, gastrocnemius, paired posterior tibial, and peroneal veins and the proximal part of the anterior tibial and proximal junctions of the greater and lesser saphenous veins.

Vein segments were assessed regarding compressibility and flow. The primary diagnostic criterion was venous incompressibility in the transverse view. Color flow findings were used to clarify the anatomic features and as supportive findings, especially in the venous segments that are less easily viewed and compressed, including the distal femoral vein at the adductor canal and the trifurcation at the proximal calf.

Examinations were performed by 1 of 2 chief radiologists (B.H.O. and P.G.V.) who subspecialized as ultrasound practitioners, both with more than 20 years of experience in venous ultrasonography. At the time of the examination, the 2 radiologists were blinded as to which group each patient was randomized. The interpretation images were recorded, and the radiologists were required to note the presence of proximal DVT (proximal to the popliteal vein) and distal DVT (the popliteal vein or the deep or muscular veins distal to the popliteal vein).

Secondary outcome measures were the Achilles tendon Total Rupture Score (ATRS),^[@bibr16-2325967120915909],[@bibr25-2325967120915909]^ the heel-rise work test,^[@bibr25-2325967120915909]^ elongation of the tendon measured with the Copenhagen Achilles ultrasonographic Length Measurement,^[@bibr8-2325967120915909]^ perimeter of the calf, return to work, and return to sport.

The primary outcome was assessed at 2 and 8 weeks. The secondary outcomes were assessed at 4, 6, and 12 months. The protocol paper provides a full description of the secondary outcomes.^[@bibr5-2325967120915909]^ No changes were made to the outcomes after commencement of the trial and publication of the protocol.

Wells Score {#section8-2325967120915909}
-----------

Several structured scoring systems have been developed to predict the risk of DVT; the most well-studied is the Wells score.^[@bibr31-2325967120915909],[@bibr34-2325967120915909],[@bibr35-2325967120915909]^ The simplified clinical model investigates the following signs, symptoms, and risk factors for DVT: active cancer, calf swelling, swollen unilateral superficial veins, unilateral pitting edema, previous documented DVT, swelling of the entire leg, localized tenderness along the deep venous system, being recently bedridden for 3 days or longer, major surgery requiring regional or general anesthetic in the past 12 weeks, and paralysis, paresis, or recent cast immobilization of the lower extremities.^[@bibr35-2325967120915909]^ The patient receives a score from --2 to 9. A score of 3 or higher indicates high probability of DVT (53%; 95% CI, 44%-61%), a score of 1 or 2 indicates moderate probability of DVT (17%; 95% CI, 13%-23%), and a score of 0 or lower indicates low probability of DVT (5.0%; 95% CI, 4%-8%).^[@bibr35-2325967120915909]^

Treatment of DVT {#section9-2325967120915909}
----------------

Patients diagnosed with DVT underwent a blood test to investigate D-dimer and plasma electrolytes. All were treated with rivaroxaban 15 mg twice a day for 3 weeks followed by 10 mg once a day for 9 weeks. After 12 weeks, a new blood test for D-dimer was performed. If D-dimer had returned to a normal value (\<0.7 FEU/mL), no further follow-up was performed. If plasma levels were above 0.7 mg/L, patients were referred to the coagulation laboratory for further investigation.

Sample Size {#section10-2325967120915909}
-----------

Based on the primary outcome of the main study (the ATRS), 130 patients were included.^[@bibr5-2325967120915909],[@bibr6-2325967120915909]^ To estimate the power in the present study, a secondary power calculation was performed before data analysis: 124 patients were required to have a 60% chance of detecting, as significant at the 5% level, a decrease in DVT from 34% in the IM group to 17% in the ECM group.

Randomization {#section11-2325967120915909}
-------------

Randomization was computer based following the random allocation rule to ensure balanced group sizes. Patients were allocated 1:1 to either the control or the intervention group. An experienced senior researcher with no other connection to the trial was responsible for generation of the allocation key and a research assistant for creation of numbered, opaque, and sealed envelopes. The allocation key was stored and accessible by only a senior researcher.

Blinding {#section12-2325967120915909}
--------

Patients were enrolled in the study by 1 of 2 designated physiotherapists at the 14-day appointment. After enrollment, the physiotherapist left the room and randomization was performed by the project nurse, who was responsible for treatment in the intervention period. Neither the patients nor the project nurse were blinded to the intervention. The project nurse prepared the patients for color Doppler sonography at the 2- and 8-week assessments. The cable strip was removed, and the patients were instructed not to reveal their allocation. The physician treating the DVTs and the primary investigator (K.W.B.) conducting the data analysis were blinded to the intervention. The allocation key was not revealed until all analyses had been performed.

Statistics {#section13-2325967120915909}
----------

Descriptive statistics were performed regarding demographic parameters. The numbers of patients with DVT in the ECM group and the IM group were compared by use of the Pearson chi-square test. To investigate the sensitivity of D-dimer, the proportion of true-positive cases (patients with elevated D-dimer and DVT) was divided by the number of patients with DVT. To investigate whether DVT influenced treatment outcome after acute Achilles tendon rupture, the population was divided into a group having DVT and a group not having DVT. Between-group differences in functional and patient-reported outcomes were investigated by use of the independent Student *t* test for normally distributed continuous data. All statistical testing was performed at the 2-sided 5% significance level. Statistical testing was performed using SPSS Statistics (Version 22; IBM).

Results {#section14-2325967120915909}
=======

From February 2014 to December 2016, 189 patients were assessed for eligibility ([Figure 2](#fig2-2325967120915909){ref-type="fig"}). Of these, 130 patients were randomized: 68 were allocated to the intervention (ECM) group and 62 to the control (IM) group. In the intervention group, 67 of 68 patients adhered to the assigned treatment; 1 did not, as he walked without the orthosis. In the control group, 56 of the 62 patients adhered to the assigned treatment; 2 persons walked without the orthosis, and 4 persons removed the cable strip. Baseline data of the population are shown in [Table 1](#table1-2325967120915909){ref-type="table"}. The training diaries were returned by 44 of 68 patients in the intervention group. All returned diaries revealed greater than 80% adherence to the training protocol. No statistically significant differences were found between responders and nonresponders when we analyzed baseline data and outcomes.

![CONSORT (Consolidated Standards of Reporting Trials) flowchart. DVT, deep vein thrombosis.](10.1177_2325967120915909-fig2){#fig2-2325967120915909}

###### 

Baseline Data*^a^*

![](10.1177_2325967120915909-table1)

  Intervention and Control Groups                                                          
  ------------------------------------------ ---------------------- ---------------------- ------------------------------
  Age, y                                     41.0 ± 9.3 (n = 68)    42.7 ± 1.7 (n = 62)    --1.7 (--5.3 to 2.0)
  Weight, kg                                 85.5 ± 13.7 (n = 61)   87.3 ± 14.4 (n = 59)   --1.8 (--6.9 to 3.3)
  Height, cm                                 180.4 ± 7.8 (n = 66)   178.3 ± 8.0 (n = 61)   2.1 (--0.6 to 4.9)
  Female                                     12/68 (18)             11/62 (18)             
  Diabetes                                   2/68 (3)               0/62 (0)               
  Elevated blood pressure                    5/68 (7)               6/62 (10)              
  Rheumatism                                 1/68 (1)               0/62 (0)               
  ASA score                                  60/68 (87)             58/62 (94)             
  Smoker                                     18/68 (27)             15/62 (25)             
  Patients Who Did and Did Not Develop DVT                                                 
                                             No DVT                 DVT                    Difference of Means (95% CI)
  Age, y                                     40.6 ± 10.2 (n = 68)   43.1 ± 10.8 (n = 62)   --2.5 (--6.1 to 1.2)
  Weight, kg                                 87.1 ± 15.5 (n = 63)   85.6 ± 12.4 (n = 57)   1.5 (--3.6 to 6.6)
  Height, cm                                 178.6 ± 7.7 (n = 67)   180.2 ± 8.2 (n = 60)   --1.5 (--4.3 to 1.3)
  Female                                     14/68 (21)             9/62 (15)              
  Diabetes                                   0/62 (0)               2/60 (3)               
  Elevated blood pressure                    6/68 (9)               5/62 (8)               
  Rheumatism                                 1/68 (2)               0/62 (0)               
  ASA score                                  60/68 (87)             58/62 (94)             
  Smoker                                     19/67 (28)             14/60 (23)             

*^a^*Data are presented as mean ± SD for continuous data and n/N (%) for dichotomous data. Difference of means was tested using the Student independent *t* test for continuous data and chi-square or Fisher exact test for dichotomous data. ASA, American Society of Anesthesiologists; DVT, deep vein thrombosis.

All patients were available for follow-up at 2 and 8 weeks. At 1 year, 5 patients were lost to follow-up in the ECM group and 3 in the IM group, leaving 63 and 59 patients, respectively ([Figure 2](#fig2-2325967120915909){ref-type="fig"}). In total, 62 of 130 patients (47.7%) developed DVT, but only 3 patients (3/130; 2.3%) developed above-knee DVT and only 1 patient presented with clinical symptoms of DVT. No patient developed symptomatic pulmonary embolism or other severe complications of DVT. The majority of the below-knee DVTs were situated in the muscle veins. ECM of the ankle did not statistically significantly affect the risk of development of DVT ([Table 2](#table2-2325967120915909){ref-type="table"}).

###### 

Primary Outcome Analysis for DVT*^a^*

![](10.1177_2325967120915909-table2)

                                  Early Controlled Motion   Immobilization                                
  ------------------------------- ------------------------- ------------------ ------- ------------------ -------
  Intention-to-treat analysis                                                                             
   DVT at any time                33/68                     48.5 (36.7-60.4)   28/61   46.8 (35.7-58.4)   .84
   DVT at 2 wk                    23/68                     33.8 (22.6-45.1)   23/62   37.1 (25.6-48.6)   .7
   DVT at 8 wk                    22/58                     37.9 (26.4-49.5)   22/61   36.1 (24.7-47.5)   .83
   Developed DVT from 2 to 8 wk   10/58                     17.2 (8.3-26.2)    7/61    11.5 (3.9-19.1)    .37
   Above-knee DVT at any time     1/68                      1.5 (0-4.3)        2/62    3.2 (0-7.4)        ≥.999
  Per-protocol analysis                                                                                   
   DVT at any time                33/67                     49.3 (37.4-61.1)   26/56   46.4 (34.6-58.3)   .76
   DVT at 2 wk                    23/67                     34.3 (23.0-45.6)   21/56   37.5 (26.0-49.0)   .72
   DVT at 8 wk                    22/58                     37.9 (26.4-49.5)   20/56   35.7 (24.3-47.1)   .81
   Developed DVT from 2 to 8 wk   10/58                     17.2 (8.3-26.2)    6/56    10.7 (3.4-18.1)    .32
   Above-knee DVT at any time     1/67                      1.5 (0-4.4)        2/56    6.6 (0-8.0)        ≥.999

*^a^*DVT, deep vein thrombosis. Difference of means was tested using the chi-square or Fisher exact test for dichotomous data.

D-dimer at the time of DVT was available in 52 of the 62 patients diagnosed with DVT. The sensitivity of D-dimer for predicting DVT was 71% (37/52). However, of the 3 patients who had above-knee DVT, only 1 had a D-dimer level above the threshold of 0.7 FEU/mL, implying a sensitivity for diagnosing above-knee DVT of 33% (1/3). Of the 62 patients diagnosed with DVT, 59 had a Wells score of 3 or higher, indicating a high risk of DVT.

Treatment outcome 1 year after rupture was not statistically significantly affected by development of DVT. Neither ATRS, heel-rise work, tendon elongation, or perimeter of the calf showed statistically significant differences at 4, 6, or 12 months after injury ([Table 3](#table3-2325967120915909){ref-type="table"}). Rates of return to work and sport were also comparable between groups, with no statistically significant differences for patients with and without DVT ([Table 3](#table3-2325967120915909){ref-type="table"}). No bleeding incidents were noted in the group treated with rivaroxaban.

###### 

Secondary Outcome Analysis: Influence of DVT on Patient-Reported and Functional Outcomes*^a^*

![](10.1177_2325967120915909-table3)

                                      No DVT                  DVT                      Difference of Means (95% CI)   *P* Value
  ----------------------------------- ----------------------- ------------------------ ------------------------------ -----------
  4 months                                                                                                            
   ATRS                               56.1 ± 17.7 (n = 63)    56.5 ± 16.0 (n = 58)     --0.3 (--6.4 to 5.8)           .92
   Heel-rise work, LSI %              16.8 ± 17.3 (n = 61)    20.1 ± 19.7 (n = 52)     --3.2 (--10.2 to 3.6)          .35
   Tendon elongation, mm              18.9 ± 15.1 (n = 62)    17.8 ± 16.5 (n = 59)     1.1 (--4.6 to 6.7)             .71
   Perimeter of calf difference, mm   20.1 ± 12.2 (n = 62)    20.5 ± 12.8 (n = 58)     --0.4 (--4.9 to 4.1)           .85
  6 months                                                                                                            
   ATRS                               62.9 ± 19.1 (n = 65)    63.4 ± 19.1 (n = 59)     --0.5 (--7.0 to 6.1)           .89
   Heel-rise work, LSI %              39.4 ± 23.9 (n = 64)    41.5 ± 26.3 (n = 52)     --2.1 (--11.1 to 6.9)          .64
   Tendon elongation, mm              12.6 ± 12.7 (n = 65)    15.3 ± 14.4 (n = 58)     --2.8 (--7.6 to 2.1)           .26
   Perimeter of calf difference, mm   18.4 ± 10.5 (n = 63)    21.1 ± 11.8 (n = 58)     --2.7 (--6.7 to 1.3)           .19
  12 months                                                                                                           
   ATRS                               74.0 ± 18.6 (n = 63)    74.5 ± 17.8 (n = 59)     --0.6 (--7.1 to 6.0)           .87
   Heel-rise work, LSI %              60.5 ± 21.3 (n = 63)    57.8 ± 21.1 (n = 59)     2.7 (--4.9 to 10.3)            .48
   Tendon elongation, mm              15.2 ± 12.7 (n = 65)    17.3 ± 14.8 (n = 58)     --2.1 (--6.9 to 2.7)           .39
   Perimeter of calf difference, mm   16.4 ± 11.2 (n = 61)    20.0 ± 12.5 (n = 58)     --3.6 (--7.9 to 7.4)           .1
  Return to work, d                   56.9 ± 76.6 (n = 52)    41.8 ± 60.8 (n = 47)     15.1 (--12.7 to 42.9)          .28
  Return to sport, d                  184.8 ± 88.8 (n = 36)   192.9 ± 103.1 (n = 46)   --8.2 (--51.2 to 34.8)         .71

*^a^*Data are presented as mean ± SD. Difference of means was tested using the Student independent *t* test. ATRS, Achilles tendon Total Rupture Score; DVT, deep vein thrombosis; LSI, limb symmetry index.

Discussion {#section15-2325967120915909}
==========

No Benefit of ECM {#section16-2325967120915909}
-----------------

The most important finding of the study was that ECM exercises, as performed in the present mobilization protocol, revealed no benefit compared with immobilization in reducing the incidence of DVT in the treatment of acute Achilles tendon rupture. This was a rather surprising finding, rejecting the study hypothesis, as early mobilization is considered key in the prevention of DVT.^[@bibr11-2325967120915909]^ However, our finding is in line with a recently published RCT by Aufwerber et al,^[@bibr3-2325967120915909]^ who investigated 150 surgically treated patients. Their intervention took place the first 2 weeks after surgery: The intervention group was encouraged to practice full weightbearing and ankle motion in an orthosis, and the control group was immobilized in a plaster cast. Like us, Aufwerber et al did not find a benefit of ECM.

When interpreting the results of the present study, one should consider the following points: The first is whether the finding is generalizable to early controlled mobilization in general or whether the chosen mobilization protocol was more restrictive than other protocols, thereby rendering this specific protocol inefficient with regard to prevention of DVT. The investigated protocol allowed for only short periods of mobilization during the day, totaling approximately half an hour of mobilization per day. Other mobilization protocols allow for continuous movement of the ankle joint throughout the day by use of hinged orthoses. Also, the investigated protocol allowed only for active dorsiflexion and not for active plantarflexion. However, both active dorsiflexion and plantarflexion have been shown to lead to increased venous return.^[@bibr18-2325967120915909]^ One should be careful to generalize the finding to early mobilization protocols that differ substantially from the one used. The second point is whether a possible effect of mobilization might be masked by other, more important aspects of the treatment protocol. Patients in both groups were allowed early weightbearing. Putting weight on the foot stimulates the venous flow^[@bibr14-2325967120915909]^ and might be more effective in reducing DVT than ECM of the ankle joint in itself. The third point is whether the finding represents a true lack of difference between groups or represents a type II error. A secondary power calculation showed a 40% risk of a type II error when looking for a 50% decrease in DVT rate. Despite the very clear signal found in the present study, the possibility for a type II error must be carefully considered when interpreting the result.

DVT Did Not Affect Treatment Outcome {#section17-2325967120915909}
------------------------------------

The second main finding of the study was that DVT had no negative implication for functional and patient-reported outcomes 1 year after rupture. This is in contrast to the study by Arverud et al,^[@bibr2-2325967120915909]^ who found an odds ratio of 0.31 for having a good outcome for patients with DVT. However, in the Arverud et al^[@bibr2-2325967120915909]^ study, the division in the groups with a good and a bad outcome was based on a purpose-made, unvalidated outcome score. None of the validated outcomes show differences between the groups with and without DVT except for heel-rise height. In summary, none of the studies show convincing evidence that DVT influences short-term function of the leg. However, 1 year after DVT, postthrombotic syndrome would not have developed, and hence, negative implications due to postthrombotic syndrome are not accounted for in either study.^[@bibr9-2325967120915909]^

D-Dimer Levels Demonstrated Very Low Sensitivity in Detecting DVT {#section18-2325967120915909}
-----------------------------------------------------------------

Guidelines for diagnosis of DVT recommend stratifying patients by risk parameters.^[@bibr10-2325967120915909],[@bibr12-2325967120915909]^ Patients with high risk should undergo color Doppler sonography, whereas patients with low risk can be assessed using D-dimer.^[@bibr10-2325967120915909],[@bibr12-2325967120915909]^ Risk parameters are usually assessed with the Wells score, which is a 3-level scoring of low (≤0 points), moderate (1 or 2 points), or high (≥3 points) probability for DVT. D-dimer testing cannot be used in patients with a high Wells score because a high prevalence of DVT negatively affects the predictive value of D-dimer.^[@bibr10-2325967120915909]^ All patients in the study had moderate to high Wells scores, explaining the low sensitivity of D-dimer in the present population with a prevalence of DVT of 48%. In this population, D-dimer had a sensitivity of 71% for diagnosing DVT, thereby missing 1 in 3 patients. All patients had an estimated Wells score above 1 point, and most of the patients with a color Doppler sonography--verified DVT had an estimated Wells score of 3 points or higher.

Our finding suggests that in patients with acute Achilles tendon rupture, D-dimer testing cannot be used to rule out DVT, as their overall high risk of DVT reduces the negative predictive value of D-dimer. Our data suggest that Wells score and color Doppler sonography are more sensitive and accurate tools for the detection of DVT after acute Achilles tendon rupture, regardless of treatment protocol.

Clinical Relevance of Isolated Distal DVTs {#section19-2325967120915909}
------------------------------------------

In the present study, 59 of 62 DVTs detected were isolated distal to the knee, all except 1 were asymptomatic, and none entailed pulmonary embolism or other severe complications due to the DVT. This finding raises the question of whether the isolated distal DVTs have clinical relevance in patients with acute Achilles tendon rupture or are casual findings with no clinical relevance.

Isolated distal DVT is a variant of DVT that accounts for 23% to 59% of all DVTs.^[@bibr28-2325967120915909]^ Despite the frequent manifestation of isolated distal DVT, the treatment is diverse with no standard of care.^[@bibr27-2325967120915909],[@bibr30-2325967120915909]^ Some institutions consider distal DVTs to be without clinical relevance and thus limit color Doppler sonography to the proximal veins without extension to the distal veins, a practice that might lead to the underdiagnosis of isolated distal DVT.^[@bibr30-2325967120915909]^ Accordingly, some national clinical guidelines do not recommend treatment for isolated distal DVT because anticoagulants have been shown to increase the risk of bleeding and isolated distal DVTs are thought to be less likely to cause postthrombotic syndrome and embolize to the lungs in comparison with proximal DVTs.^[@bibr30-2325967120915909],[@bibr31-2325967120915909]^ However, the international consensus statement on prevention and treatment of venous thromboembolism indicates that oral anticoagulants should be given to all patients with symptomatic isolated distal DVT for 3 months.^[@bibr23-2325967120915909]^ It remains unknown whether isolated distal DVTs are of clinical relevance, especially if asymptomatic.

Limitations {#section20-2325967120915909}
-----------

The study was limited by the outcome being a secondary outcome to a main study. Also, the nature of the intervention is a limiting factor, as blinding of the patients was impossible. The patients could have crossed over between the intervention and control group, but we believe that we controlled for this by using training diaries in the intervention group and sealing the boot in the control group.

Conclusion {#section21-2325967120915909}
==========

The study hypotheses were rejected, as the ECM protocol revealed no benefit versus immobilization in reducing the incidence of DVT. Furthermore, DVT did not seem to negatively affect outcome at 1 year after rupture. ECM of the ankle 5 times a day from weeks 3 to 8 after rupture does not seem to be the key in reducing the risk of DVT. The large difference in incidence of isolated distal DVTs and proximal DVTs raises the question of whether below-knee DVTs are of clinical relevance.
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